Servier Collaborates with Black Diamond Therapeutics to Advance BDTX-4933 for Solid Tumors
Shots:
- Servier and Black Diamond have entered into a global licensing agreement to develop & commercialize BDTX-4933 as a potential treatment for solid tumors
- As per the deal, Servier will handle the global development & commercialization of BDTX-4933 across multiple indications, incl. NSCLC & other solid tumors, in exchange for $70M upfront & ~$710M in development & commercial milestones, plus net sales-based royalties
- BDTX-4933 is being evaluated in P-I trial, where dose escalation & expansion cohort will assess its safety, tolerability, preliminary P-II dose, & antitumor activity in adults with recurrent advanced/metastatic cancers harboring BRAF, CRAF, or NRAS mutations
Ref: Servier | Image: Servier & Black Diamond
Related News:- Servier Reports the US FDA’s Approval of Voranigo (Vorasidenib) to Treat Grade 2 IDH-Mutant Glioma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
